ARWR — Arrowhead Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $8.26bn
- $7.92bn
- $829.45m
Brief: Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran
Factbox: Fat, not muscle: Drugmakers in race for next weight-loss breakthrough
Brief: Arrowhead Pharmaceuticals Initiates Phase 1/2A Study Of Aro-Alk7 For The Treatment Of Obesity
U.S. RESEARCH ROUNDUP-Brighthouse Financial, Payoneer Global, Voya Financial
Arrowhead Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Arrowhead Pharmaceuticals Says Ken Myszkowski To Retire As CFO
Brief: Arrowhead Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Arrowhead Pharmaceuticals Announces Topline Results From Part 2 Of Phase 1/2 Study Of Aro-C3 In Patients With IgA Nephropathy
Factbox: Fat, not muscle: drugmakers in race for next weight-loss breakthrough
Arrowhead Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: S&P Dow Jones Indices Says Arrowhead Pharmaceuticals Will Replace Barnes Group Inc. In S&P Smallcap 600
Brief: Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
U.S. STOCKS ON THE MOVE-HP, Urban Outfitters, 3D Systems
Arrowhead Pharma gains as two brokerages raise PT after Sarepta deal
Arrowhead Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary
U.S. STOCKS ON THE MOVE-Goldman Sachs, Zoom, Rumble
U.S. STOCKS ON THE MOVE-Pinterest, Best Buy, Chevron
Arrowhead Pharma jumps after license agreement with Sarepta
Brief: Arrowhead Pharmaceuticals submits New Drug Application To U.S. FDA